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A reference haplotype panel for genome-wide
imputation of short tandem repeats
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Short tandem repeats (STRs) are involved in dozens of Mendelian disorders and have been
implicated in complex traits. However, genotyping arrays used in genome-wide association
studies focus on single nucleotide polymorphisms (SNPs) and do not readily allow identifi-
cation of STR associations. We leverage next-generation sequencing (NGS) from 479
families to create a SNP+ STR reference haplotype panel. Our panel enables imputing STR
genotypes into SNP array data when NGS is not available for directly genotyping STRs.
Imputed genotypes achieve mean concordance of 97% with observed genotypes in an
external dataset compared to 71% expected under a naive model. Performance varies widely
across STRs, with near perfect concordance at bi-allelic STRs vs. 70% at highly polymorphic
repeats. Imputation increases power over individual SNPs to detect STR associations with
gene expression. Imputing STRs into existing SNP datasets will enable the first large-scale
STR association studies across a range of complex traits.
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Genome-wide association studies (GWAS) have becomeincreasingly successful at identifying genetic loci sig-nificantly associated with complex traits in humans, lar-
gely due to the enormous growth in available sample sizes1–3.
Hundreds of thousands of individuals have been genotyped using
commodity genotyping arrays. These arrays take advantage of the
correlation structure between nearby variants induced by linkage
disequilibrium (LD), which allows genome-wide imputation
based on genotypes of only a small subset of loci4. However,
GWAS based on single-nucleotide polymorphism (SNP) asso-
ciations face important limitations. Even with sample sizes of up
to 100,000 individuals, common SNPs still fail to explain the
majority of heritability for many complex traits1,5.
One compelling hypothesis explaining the missing heritability
dilemma is that complex variants, such as multi-allelic repeats not
in strong LD with common SNPs, are important drivers of
complex traits but are largely invisible to current analyses. Indeed,
dissection of the strongest schizophrenia association, located in
the major histocompatibility complex, revealed a poorly tagged
polymorphic copy number variant (CNV) to be the causal var-
iant6. The signal could not be localized to a single SNP and could
only be explained after deep characterization of the underlying
CNV. This and subsequent discoveries7,8 highlight the impor-
tance of considering alternative variant classes.
Short tandem repeats (STRs), consisting of repeated motifs of
1–6 bp in tandem, comprise more than 3% of the human gen-
ome9. Multiple lines of evidence support a role of STRs in
complex traits10–12, particularly in neurological and psychiatric
phenotypes. Due to their rapid mutation rates13, STRs exhibit
high rates of heterozygosity14 and likely contribute at least as
many de novo mutations per generation as SNPs15,16. Further-
more, STRs have been shown to play a significant role in reg-
ulating gene expression17,18, splicing19–21, and DNA
methylation18. Intriguingly, more than 30 Mendelian disorders
are caused by STR expansions via a range of mechanisms,
including polyglutamine aggregation (Huntington’s Disease,
ataxias22), hypermethylation (Fragile X Syndrome23), and RNA
toxicity (ALS/FTD24). Furthermore, causal STRs driving existing
GWAS signals have already been identified25.
Existing technologies have not allowed for systematic STR
association studies. Next-generation sequencing (NGS) can be
used to directly genotype short STRs, but NGS is still too
expensive to perform on sufficiently large cohorts for GWAS of
most complex traits. An alternative approach is to impute STRs
into existing SNP array datasets. Previous studies have demon-
strated that STRs are often in significant LD with nearby SNPs26–
28 and found that STRs and SNPs provide complementary
information about the evolutionary history of a genomic region.
Despite widespread SNP-STR LD, statistical phasing of STRs and
SNPs is challenging for several reasons: SNP-STR LD is notably
weaker than SNP-SNP LD28 due to the rapid mutation rates13,29
and high prevalence of recurrent mutations in STRs. As a result,
the relationship between STR repeat number and SNP haplotype
can be complex: the same STR allele may be present on multiple
SNP haplotypes. On the other hand, a single SNP haplotype may
harbor multiple distinct STR alleles. Furthermore, LD patterns at
STRs vary widely as a function of properties of the repeat, such as
the repeat unit length, mutation rate, and mutation step size28.
Finally, STRs are prone to genotyping errors induced during PCR
amplification30,31, further ambiguating phase information.
Sequencing related samples allows haplotype resolution by
directly tracing inheritance patterns. The recent generation of
deep NGS using PCR-free protocols for hundreds of nuclear
families in combination with accurate tools for genotyping STRs
from NGS32 now enables applying this technique genome-wide.
Here, we profile STRs in 479 families and use pedigree
information to phase STR genotypes onto SNP haplotypes to
create a genome-wide reference for imputation. We use this panel
to impute STRs into an external dataset of similar ethnic back-
ground with average 97% concordance with observed STR gen-
otypes. Imputation accuracy varies across STRs, ranging from
nearly perfect concordance at bi-allelic STRs to around 70% for
highly polymorphic forensic markers. We show that STR impu-
tation achieves greater power than individual SNPs to detect
underlying STR associations and demonstrate the utility of our
panel by detecting STRs not previously known to be associated
with gene expression. Finally, we impute genotypes at STRs
previously implicated in human disorders and show that we could
accurately identify specific SNP haplotypes associated with long
normal alleles most at risk for expansion.
To facilitate use by the community, we release a phased SNP+
STR haplotype panel for samples genotyped as part of the 1000
Genomes Project (see Data availability). This resource will enable
large-scale studies of STR associations in hundreds of thousands
of available SNP datasets, and will likely yield significant new
insights into complex traits.
Results
A catalog of STR variation in 479 families. We first generated a
genome-wide catalog of STR variation in a cohort of families
included in the Simons Simplex Collection (SSC) (see URLs). We
focused on 1916 individuals from 479 family quads (parents and
two children) that were sequenced to an average depth of 30x
using Illumina’s PCR-free protocol. Based on comparison to 1000
Genomes Project samples, we estimated the cohort to consist
primarily of Europeans (83%), with 2.0%, 9.0%, and 3.6% of East
Asian, South Asian, and African ancestry, respectively (Supple-
mentary Fig. 1). We used HipSTR32 to profile autosomal STRs in
each sample. HipSTR takes aligned reads and a reference set of
STRs as input and outputs maximum likelihood diploid geno-
types for each STR in the genome. While HipSTR infers the entire
sequence of each STR allele, we focus here on differences in
repeat copy number rather than sequence variation within the
repeat itself. To maximize the quality of genotype calls, indivi-
duals were genotyped jointly with HipSTR’s multi-sample calling
mode using phased SNP genotypes and aligned reads as input
(Methods). Multi-sample calling allows HipSTR to leverage
information on haplotypes discovered across all samples in the
dataset to estimate per-locus error parameters and output geno-
type likelihoods for each possible diploid genotype. Notably, our
HipSTR catalog excluded most known STRs implicated in
expansion disorders such as Huntington’s Disease and hereditary
ataxias, since even the normal allele range for these STRs is above
or near the length of Illumina reads33–36. To supplement our
panel, we applied a second STR genotyper, Tredparse37, to gen-
otype a targeted set of known pathogenic STRs in our cohort
(Supplementary Table 1). Tredparse incorporates multiple fea-
tures of paired-end reads to estimate the size of repeats longer
than the read length. For seven STRs called by both Tredparse
and HipSTR, Tredparse genotypes were used for downstream
analyses.
An average of 1.14 million STRs passed HipSTR’s default
filtering settings in each sample (Fig. 1a). We obtained at least one
call for 97% of all STRs in the HipSTR reference of 1.6 million
STRs and for 15 of 25 STRs in the Tredparse reference with an
average overall call rate of 90% (Fig. 1b). We applied additional
stringent genotype quality filters to ensure accurate calls for
downstream phasing and imputation analysis. STRs overlapping
segmental duplications, with call rates <80%, or with genotype
frequencies unexpected under Hardy-Weinberg Equilibrium were
removed (Methods). We further removed STRs with low expected
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heterozygosity (<0.095) to restrict analysis to polymorphic STRs.
We found that these filters increased the quality of our calls, as
evidenced by the average Mendelian inheritance rate of 99.8%
and 97.9% at STRs that passed and failed quality filters,
respectively (Fig. 1c). After filtering, 453,671 and 9 STRs from
the HipSTR and Tredparse panels, respectively, remained in our
catalog.
We further assessed the quality of our STR genotypes by
comparing patterns of variation from SSC to previous catalogs of
STR variation obtained using a distinct set of samples and STR
genotyping methods. We found that per-locus heterozygosities
(Methods) were highly concordant with a catalog generated from
the 1000 Genomes Project38 data using lobSTR39. (Pearson r=
0.96; p < 10−200; n= 386,100) (Fig. 1d). Allele length distributions
at known pathogenic STRs observed in SSC matched closely to
previously reported normal allele frequencies at each STR
(Fig. 1e). For STRs genotyped both by HipSTR and Tredparse,
estimated repeat lengths were highly concordant (average
concordance 99.4%, Supplementary Table 1). Overall, these
results show that our catalog consists of robust STR genotypes
suitable for downstream phasing and imputation analysis.
A genome-wide SNP+ STR haplotype reference panel. We
examined the extent of linkage disequilibrium between STRs and
nearby SNPs using two metrics. The first, termed length r2, is
defined as the squared Pearson correlation between STR allele
length and the SNP genotype. The second, termed allelic r2, treats
each STR allele as a separate bi-allelic locus and is computed
similar to traditional SNP-SNP LD (Methods). Similar to pre-
vious studies28, SNP-STR LD was dramatically weaker than SNP-
SNP LD by both metrics (Supplementary Fig. 2a) with length r2
generally stronger than allelic r2. We additionally determined the
best tag SNP (Methods) for each STR, which was on average 5.5
kb away (Supplementary Fig. 2b). Nearly all STRs were in sig-
nificant LD (length r2 p < 0.05) with the best tag SNP, suggesting
that phasing would result in informative haplotypes.
We developed a pipeline to phase STRs onto SNP haplotypes
leveraging the quad family structure (Fig. 2a). Based on our LD
analysis, we used a window size of ± 50 kb to phase each STR
separately using Beagle40, which was recently demonstrated to
perform well in phasing multi-allelic STRs41 and can incorporate
pedigree information. Resulting phased haplotypes from the
parent samples were merged into a single genome-wide reference
panel for downstream imputation.
We first evaluated the utility of our phased panel for
imputation using a leave-one-out analysis in the SSC samples.
For each sample, we constructed a modified reference panel with
that sample’s haplotypes removed and then performed genome-
wide imputation. We measured concordance, length r2, and allelic
r2 between imputed vs. observed genotypes at each STR, where
observed refers to genotypes obtained by HipSTR or Tredparse.
We additionally evaluated imputation performance under two
null models where genotypes were either imputed randomly
(random model) or always imputed as the most frequent diploid
genotype (naive model) (Methods). Imputed genotypes showed
an average of 96.7% concordance with observed genotypes,
compared to 61.0% or 71.7% expected under the random and
naive models, respectively (Table 1). As expected, concordance
was strongest at the least polymorphic STRs (Fig. 2b, Supple-
mentary Fig. 3a) and allelic r2 was highest for the most common
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alleles (Supplementary Fig. 3b). Length r2 was not strongly
associated with expected heterozygosity, although the least and
most heterozygous STRs tended to have lower length r2
(Supplementary Fig. 3c). Imputation metrics were weakly
negatively correlated with distance to the best tag SNP (Pearson
r=−0.06; p= 0.06, Pearson r=−0.04; p= 0.27; and Pearson r
=−0.06, p= 7.5 × 10−5 between distance to the best tag SNP and
concordance, length r2, and allelic r2, respectively). To further
evaluate imputation performance at highly polymorphic STRs, we
examined the CODIS STRs used in forensic analysis (Supple-
mentary Table 2). Per-STR concordances were highly correlated
with imputation results recently reported by Edge et al.41
(Pearson r2= 0.93; p=6.3 × 10−6; n= 10), but were on average
8.8% higher (average concordance 69.1% vs. 60.3% using our
panel vs. in Edge et al.41 restricting to STRs imputed in both
studies), likely as a result of our larger and more homogenous
cohort. Per-locus imputation statistics for all STRs are reported in
Supplementary Data 1 and 2).
We next evaluated our ability to impute STR genotypes into
external datasets. For this, we focused on samples from the 1000
Genomes Project38 with high quality SNP genotypes obtained
from low coverage whole-genome sequencing (WGS) (n= 2504)
or genotyping arrays (n= 2486 for Affy 6.0, and n= 2318 for
Omni 2.5). We validated imputed genotypes for subsets of 1000
Genomes samples using data obtained from three pipelines: (1)
Illumina WGS+HipSTR, (2) capillary electrophoresis, and (3)
10X Genomics+HipSTR, in each case using the orthogonal data
as the truth set. Each of these datasets evaluates a different aspect
of our imputation pipeline. The first tests whether a pipeline
identical to that used to create our reference panel can achieve
similar performance on datasets collected by different groups
using different protocols. Additionally, since it consists of both
Europeans and non-Europeans, it allows us to evaluate imputa-
tion across a variety of population groups. The second tests
whether our results are robust across STR genotyping technol-
ogies and allows us to compare imputed STRs based on
statistically inferred HipSTR genotypes to those obtained
experimentally using capillary electrophoresis. The third returns
phased genotypes, allowing us to directly compare inferred
haplotypes and phase information.
First, we used HipSTR to genotype STRs in separate high-
coverage (30×) WGS datasets available for 150 of the samples (see
URLs) from European (n= 50), African (n= 50), and East Asian
(n= 50) backgrounds. Per-locus concordance, length r2, and
allelic r2 were highly concordant between the SSC panel and 1000
Genomes samples of European origin (Pearson r= 0.94, 0.63, and
0.85, respectively) (Fig. 2c; Supplementary Fig. 5; Table 1).
Overall imputation performance did not vary when using phased
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genotypes obtained from WGS vs. Omni2.5 for imputation
(Supplementary Table 3). Concordance was noticeably weaker in
African and East Asian samples, likely due to different population
background compared to the SSC samples and lower LD in
African populations42.
Next, we compared imputed genotypes to capillary electro-
phoresis data43 (see URLs) available for a subset of samples in our
panel at highly polymorphic STRs. After filtering non-European
samples and STRs that could not be reliably mapped to HipSTR
notation (Methods), 41 samples and 206 STRs remained for
comparison. We obtained an average overall concordance of
76.9% with capillary genotypes compared with 76.4% expected
based on HipSTR analysis. Per-locus concordances based on
HipSTR vs. capillary genotypes were strongly correlated (Pearson
r= 0.83; p= 1.05 × 10−53; n= 206) (Fig. 2d).
Finally, we compared imputed genotypes from the highly
characterized NA12878 genome to phased data available from
10X Genomics (see URLs), a synthetic long read technology. We
constructed a phased validation panel by calling HipSTR
separately on reads from each phase and combining with phased
SNP genotypes (Methods, Supplementary Fig. 6). We could
obtain phased 10X calls for 116,764 of the STRs in our panel. We
used the nearest heterozygous SNP to each STR to match phase
order between our panel and the 10X data, which allowed us to
directly compare imputed alleles and evaluate phase accuracy.
Overall, imputed STR alleles showed 96% concordance with those
obtained from 10X and per-locus genotype concordance was
consistent with concordance metrics measured in SSC (Fig. 2e).
Taken together, validation of imputed STR genotypes against
three separate truth sets demonstrates the accuracy of our original
SNP+ STR haplotype panel and shows that our quality metrics
are reliable indicators of per-STR imputation performance across
datasets.
Imputation increases power to detect STR associations. We
sought to determine whether our SNP+ STR haplotype panel
could increase power to detect underlying STR associations over
standard GWAS. First, we simulated phenotypes based on a
single causal STR and examined the power of the imputed STR
genotypes vs. nearby SNPs to detect associations. We focused
primarily on a linear additive model relating STR dosage, defined
as the average allele length, to quantitative phenotypes (Fig. 3a),
since the majority of known functional STRs follow similar
models (e.g., refs. 17,21,44,45). Association testing simulations were
performed 100 times for each STR on chromosome 21 in our
dataset (Methods). As expected, the strength of association for
each variant as measured by the negative log10 p-value was lin-
early related with its length r2 with the causal variant (Fig. 3b).
On average, imputed STR genotypes explained 17.7% more var-
iation in STR allele length compared to the best tag SNP (mean
length r2= 0.92 and 0.74 for imputed STRs vs. SNPs, respec-
tively). The advantage from STR imputation grew as a function of
the number of common STR alleles (Supplementary Fig. 7).
Imputed genotypes showed a corresponding increase in power to
detect associations at a given p-value threshold (Fig. 3c). Similar
trends were observed for case–control traits (Supplementary
Fig. 8). We additionally tested the ability of imputed STR geno-
types to identify associations due to non-linear models relating
STR genotype to phenotype (Supplementary Fig. 9). While both
STR and SNP-based tests had limited power to detect non-linear
associations, per-allele STR association tests had higher power
than the best tag SNP in 60% of simulations. Importantly, testing
for complex models relating repeat length to phenotype will only
be possible when allele lengths are available, thus demonstrating
an additional need for STR imputation over SNP-based tests to
detect these associations.
We next determined whether STR imputation could identify
STR associations using real phenotypes. We focused on gene
expression, given the large number of reported associations
between STR length and expression of nearby genes in cis17,18
(termed eSTRs). To this end, we analyzed eSTRs from samples
in the Genotype-Tissue Expression46 (GTEx) dataset for which
RNA-sequencing, WGS, and SNP array data were available. As
a test case, we imputed STR genotypes using SNP data for
chromosome 21 and tested for association with genes expressed
in whole blood. For comparison, we additionally performed
each association using genotypes obtained from WGS using
HipSTR (Methods). A total of 2452 STR x gene tests were
performed in each case. Association p-values were similarly
distributed across both analyses and showed a strong departure
from the uniform distribution expected under a null hypothesis
of no eSTR associations (Fig. 3d). For all nominally significant
associations (p < 0.05), effect sizes were strongly correlated
when using imputed vs. HipSTR genotypes (Pearson r= 0.99; p
= 1.01 × 10−79, n= 97). Furthermore, effect sizes obtained
from imputed data were concordant with previously reported
effect sizes in a separate cohort using a different cell type
(lymphoblastoid cell lines)17 (Pearson r= 0.79; p= 0.0042, n=
11) (Fig. 3e).
Table 1 Imputation performance summary
Panel (n= number of
samples)
Observed
concordance
Naive
concordance
Random
concordance
Observed
length r2
Random
length r2
Observed
allelic r2
Random
allelic r2
SSC—LOO (n= 1916) 96.7% 71.7% 61.0% 0.906 0.605 0.861 0.552
SSC—LOO (multi-allelic) 94.3% 62.2% 48.5% 0.888 0.334 0.800 0.333
1000 Genomes—EUR
(n= 49)
97.0% 75.1% 63.2% 0.921 0.678 0.892 0.543
1000 Genomes—EUR
(multi-allelic)
94.8% 66.6% 50.0% 0.900 0.334 0.828 0.314
1000 Genomes—AFR
(n= 46)
90.6% 70.2% 57.9% 0.746 0.619 0.706 0.493
1000 Genomes—AFR
(multi-allelic)
85.6% 61.1% 44.4% 0.708 0.336 0.653 0.310
1000 Genomes—EAS
(n= 45)
93.8% 77.2% 66.0% 0.823 0.690 0.781 0.557
1000 Genomes—EAS
(multi-allelic)
89.4% 69.7% 53.7% 0.780 0.336 0.663 0.313
Results indicate mean across all STRs analyzed. Allelic r2 values include all common alleles (frequency at least 5%). Multi-allelic refers to STRs with three or more common alleles. Naive and random
denote the two null imputation models as defined in the Methods
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We identified genes for which the STR is most likely the causal
variant and tested whether STR imputation had greater power to
identify causal eSTRs compared to SNP-based analyses. We used
ANOVA model comparison to determine genes for which the
STR explained additional variation over the top SNP (Methods).
We additionally applied CAVIAR47 to fine-map associations
using the most strongly associated STR and the top 100 associated
SNPs for each gene (Methods). We identified three genes with
ANOVA p < 0.05 for which the STR was the top variant returned
by CAVIAR. One example, a CG-rich STR in the promoter of
CSTB, was previously demonstrated to act as an eSTR48 and
expansions of this repeat are implicated in myoclonus epilepsy49.
In each case, imputed STR genotypes were more strongly
associated with gene expression compared to the best tag SNP
(Fig. 3f–g, Supplementary Table 4).
Imputing normal alleles at known pathogenic STRs. Finally, to
determine whether alleles at known pathogenic STRs could be
accurately imputed, we examined results of our imputation
pipeline at 12 STRs previously implicated in expansion disorders
that were included in our panel (Table 2). Our analysis focused
on alleles in the normal repeat range for each STR, since
pathogenic repeat expansions at these STRs are unlikely to be
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Fig. 3 STR imputation improves power to detect STR associations. a Example simulated quantitative phenotype based on SSC genotypes. A quantitative
phenotype was simulated assuming a causal STR (red). Power to detect the association was compared between the causal STR, imputed STR genotypes,
and all common SNPs (MAF > 0.05) within a 50 kb window of the STR (gray). b Strength of association (-log10 p) is linearly related with LD with the causal
variant. For SNPs, the x-axis gives the length r2 calculated using observed genotypes. For the imputed STR (blue), the x-axis gives the length r2 from leave-
one-out analysis. c The gain in power using imputed genotypes is linearly related to the gain in length r2 compared to the best tag SNP. Gray contours give
the bivariate kernel density estimate. Top and right gray area gives the distribution of points along the x- and y-axes, respectively. Power was calculated
based on the number of simulations out of 100 with nominal p < 0.05. d Quantile-quantile plot for eSTR association tests. Each dot represents a single
STR×gene test. The x-axis gives the expected log10 p-value distribution under a null model of no eSTR associations. Red and blue dots give log10 p-values
for association tests using HipSTR genotypes and imputed STR genotypes, respectively. Black dashed line gives the diagonal. e Comparison of eSTR effect
sizes using observed vs. imputed genotypes. Each dot represents a single STR×gene test. The x-axis gives effect sizes obtained using imputed genotypes.
Gray dots give the effect size in GTEx whole blood using HipSTR genotypes. Purple dots give effect sizes reported previously17 in lymphoblastoid cell lines.
f, g Example putative causal eSTRs identified using imputed STR genotypes. Left, middle, and right plots give HipSTR STR dosage (red), imputed STR
dosage (blue), and the best tag SNP genotype (gray) vs. normalized gene expression, respectively. STR dosage is defined as the average length difference
from hg19. One dot represents one sample. P-values are obtained using linear regression of genotype vs. gene expression. STR and SNP sequence
information is shown for the coding strand. Gene diagrams are not drawn to scale
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present in the SSC cohort. Notably, accurate imputation of non-
pathogenic allele ranges is still informative as (1) long normal or
intermediate size alleles may result in mild symptoms in some
expansion disorders50–52 (2) longer alleles are more at risk for
expansion53 and (3) allele lengths below the pathogenic range
could potentially be associated with more complex phenotypes51.
Similar to the CODIS markers, these STRs are highly
polymorphic with 10 or more alleles per locus. In all cases,
imputed genotypes were more strongly correlated with observed
genotypes compared to the best tag SNP. Where both HipSTR
and Tredparse genotypes were available, concordance results were
nearly identical across all STRs (Supplementary Table 5).
Visualization of SNP-STR haplotypes at the CAG repeat
implicated in dentatorubral-pallidoluysian atrophy (DRPLA)54
reveals a typical complex relationship between STR allele length
and local SNP haplotype (Fig. 4a), with the same STR allele often
present on multiple SNP haplotype backgrounds. Still, for most
STRs there is a clear association of specific haplotypes with
different allele length ranges allowing accurate imputation across
a large range of allele sizes (Fig. 4b, Supplementary Fig. 10).
Resolution of SNP-STR haplotypes can be used to infer the
mutation history of a specific STR locus26,27. Notably, for many
STR expansion orders it has been shown that pathogenic
expansion alleles originated from a founder haplotype55–58
associated with a long allele. We compared SNP haplotypes at
the DRPLA locus in our dataset to a previously reported founder
haplotype55. In concordance with the hypothesis of a single
founder haplotype, we found that SNP haplotypes with smaller
Hamming distance to the known founder haplotype had longer
CAG tracts (Pearson r=−0.79; p < 10−200). This finding
demonstrates that while we were unable to directly impute
pathogenic expansion alleles, STR imputation can accurately
identify which individuals are at risk for carrying expansions or
pre-pathogenic mutations and the inferred haplotypes can reveal
the history by which such mutations arise.
Discussion
Our study combines available whole-genome sequencing datasets
with existing bioinformatics tools to generate the first phased
SNP+ STR haplotype panel allowing genome-wide imputation of
STRs into SNP data. Despite their exceptionally high rates of
polymorphism, 92% of STRs in our panel could be imputed with
at least 90% concordance, and 38% achieved greater than 99%
concordance. Imputation performance varied widely across STRs,
primarily due to differences in polymorphism levels across loci.
Bi-allelic STRs could be imputed nearly perfectly (average con-
cordance >99%, compared to 80% expected under a naive model),
whereas STRs with the highest heterozygosity, including forensic
markers and known pathogenic repeats, could be imputed to
around 70% concordance (compared to approximately 50%
expected under a naive model). We additionally show that
imputation improves power to detect STR associations over
standard SNP-based GWAS and could detect both known and
previously unknown associations between STR lengths and
expression of nearby genes.
A widely recognized limitation of GWAS is the fact that
common SNP associations still explain only a small fraction of
heritability of most traits. Multiple explanations for this have
been proposed, including minute effect sizes of individual var-
iants and a potential role for high-impact rare variation59.
However, studies in large cohorts reaching hundreds of thousands
of samples1–3, as well as deep sequencing studies to detect rare
variants60, have so far not confirmed these hypotheses. An
increasingly supported idea is that complex variants not well
tagged by SNPs may comprise an important component of the
missing heritability10–12. GWAS is essentially blind to contribu-
tions from highly polymorphic STRs and other repeats, despite
their known importance to human disease and molecular phe-
notypes. Thus, STR association studies will undoubtedly uncover
additional heritability that is so far unaccounted for. Notably,
while autism phenotypes are available for the SSC families, this
cohort is too small to perform a GWAS and was specifically
ascertained for families enriched for de novo, rather than inher-
ited, pathogenic mutations. In future work our panel can be
applied to impute STRs into larger cohorts for autism and other
complex traits for which tens of thousands of SNP array datasets
are available.
Our initial haplotype panel faces several important limitations.
First, the majority of samples are of European origin, limiting
imputation accuracy in other population groups. Second, impu-
tation accuracy is mediocre for the most highly polymorphic
STRs, some of which will ultimately have to be directly genotyped
to adequately test for associations. Notably, our work relied on
existing tools originally designed for SNP imputation. Further
work on computational methods specifically for imputing repeats
may be able to improve performance. Finally, thousands of long
STRs are filtered from our panel due to the limitation imposed by
short read lengths. While we have included target STRs impli-
cated in STR expansion disorders, many long STRs are still
Table 2 Imputation performance at known pathogenic repeats
Locus Motif Disordera Length r2
LOO
Observed
concordance
Naive
concordance
Random
concordance
Best tag SNP r2bestSNP
3:63898362 CAG SCA7 0.75 92.0% 75.6% 63.9% rs58676857 0.57
4:3076604 CAG HD 0.47 64.3% 39.4% 27.5% rs762855 0.11
5:146258292 CAG SCA12 0.88 93.8% 59.9% 46.3% rs2082405 0.64
6:16327867 CAG SCA1 0.72 85.3% 55.0% 33.8% rs17860797 0.04
6:170870996 CAG SCA17 0.51 80.0% 39.8% 31.5% rs9472489 0.15
12:112036755 CAG SCA2 0.49 96.2% 88.2% 80.2% rs148019457 0.28
12:7045892 CAG DRPLA 0.86 81.2% 38.8% 24.9% rs34199021 0.69
13:70713516 CTG/
CAG
SCA8 0.87 84.7% 27.0% 24.0% rs9564660 0.39
14:92537355 CAG SCA3 0.88 86.4% 33.8% 27.5% rs7144492 0.27
16:87637894 CAG HDL 0.55 88.2% 55.2% 46.5% rs2434850 0.34
19:46273463 CTG DM1 0.87 86.9% 39.4% 30.8% rs7254351 0.44
19:13318673 CAG SCA6 0.81 92.0% 44.1% 39.2% rs2070737 0.63
aHD Huntington’s disease; SCA spinocerebellar ataxia, DRPLA Dentatorubral-pallidoluysian atrophy, DM1 myotonic dystrophy type 1, HDL huntington’s disease-like 2. The best tag SNP for an STR is
defined as the SNP within 50 kb with the highest length r2. LOO refers to leave-one-out analysis in the SSC cohort r2bestSNP gives the length r
2 between STR genotype length and the genotype of the best
tagging SNP within 50 kb of the STR
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inaccessible using current tools. New methods are now being
developed for genome-wide genotyping of more complex
STRs37,61 and longer variable number tandem repeats (VNTRs)62
from short reads and can be used to expand our panel in the
future. Overall, our STR imputation framework will enable an
entire new class of variation to be interrogated by reanalyzing
hundreds of thousands of existing datasets, with the potential to
lead to novel genetic discoveries across a broad range of
phenotypes.
Methods
SSC Dataset. The SSC Phase 1 dataset consists of 1916 individuals from 479 quad
families. Access to SSC data was approved for this project under SFARI Base
project ID 2405.1. This study was certified as exempt from institutional review
board (IRB) review by the University of California San Diego IRB (Project
#161286XX) since only de-identified data was accessed. Informed consents were
obtained for each participating family by SSC recruitment sites in accordance with
their local IRBs.
Aligned BAM and gVCF files for whole-genome sequencing data of individuals
were obtained through SFARI base (see URLs) and processed on Amazon Web
Services (AWS). SNP genotypes were called from gVCF files using the GATK
version 3 joint calling pipeline63. A total of 27,185,239 variants that passed the
default GATK filters and overlapped with sites reported in the 1000 Genomes
Project38 phase 3 data were retained for downstream analysis.
We performed principal components analysis (PCA) using SNPs from
2504 samples from Phase 3 of the 1000 Genomes Project38 and projected SSC
samples onto the resulting PCs to infer sample ancestry (Supplementary Fig. 1). We
estimated that the SSC cohort consists of 1585 Europeans, 39 East Asian, 172 South
Asian, 69 African samples, and 51 individuals that did not clearly belong to any
single population group.
Genome-wide multi-sample STR genotyping. STRs were jointly genotyped on
the AWS EC2 platform in batches of 500 STRs. We streamed the corresponding
region of each BAM file and of the phased SNP VCF files to a local EBS volume
attached to each EC2 instance using samtools64 version 1.4 and tabix65 version 1.2,
respectively. HipSTR32 version v0.5 was called individually per STR with default
parameters. Phased SNPs were provided as input to allow HipSTR to perform
physical phasing when possible. Resulting VCF files from each batch were merged
to create a genome-wide callset in VCF format.
HipSTR calls were filtered using the filter_vcf.py script in the HipSTR package
with suggested parameters (--min-call-qual 0.9 --max-call-flank-indel 0.15 --max-
call-stutter 0.15). We used the following criteria to remove problematic STRs from
the callset: (i) STRs overlapping segmental duplications (UCSC Table Browser66
hg19.genomicSuperDups table) were removed from the callset using intersectBed67
v2.25.0; (ii) Pentanucleotides and hexanucleotides containing homopolymer runs
of at least 5 or 6 nucleotides, respectively, in the hg19 reference genome were
removed as they were found to contain an excess of indels in the homopolymer
regions; (iii) STRs with call rate <80%; (iv) STRs with expected heterozygosity
<0.095, corresponding to a minor allele frequency of 5% for bi-allelic markers, were
removed to restrict to polymorphic STRs; (v) STRs with significantly more or fewer
heterozygous genotypes compared to expectation under Hardy-Weinberg
equilibrium (p < 0.01) as suggested previously68. After filtering, 453,671 STRs
remained in our panel.
Genotyping clinically relevant STRs. A total of 25 clinically relevant STRs were
called using Tredparse37 v0.75 from the aligned BAM files obtained through SFARI
base on Amazon EC2. Default profiles containing information about the genomic
position, reference repeat length, and repeat motif supplied with the software were
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used. We filtered STRs with call rate less than 80% or for which only a single allele
was identified (Supplementary Table 1). Nine STRs remained after filtering.
Computing expected STR heterozygosity. For an STR with alleles {1...n}, let pi be
the frequency of the ith allele computed from observed genotypes. Expected STR
heterozygosity is defined as: H ¼ 1Pni¼1 p2i . For this study all alleles with
identical length are treated as the same allele. On average each length-based allele
corresponded to 1.8 sequence-based alleles.
Comparison to 1000G catalog. STR genotypes for 1000 Genomes samples gen-
erated by Willems et al.14 were downloaded from the strcat site (see URLs).
Expected heterozygosity was computed using the PyVCF package (see URLs) for
the 1000 Genomes calls and using a custom script for the SSC data to collapse
alleles of identical length into a single allele. STRs passing all filters described above
included in the comparison. Analysis was restricted to STRs with at least 500 calls
in the 1000 Genomes dataset.
Normal allele frequency distributions at pathogenic STRs. Control distribu-
tions for Fig. 1e were obtained from previous studies of normal alleles at known
pathogenic STRs. Allele frequencies for SCA1, SCA2, SCA3, SCA6, SCA12, SCA8,
SCA17, and DRPLA were obtained from Fig. 1 of Majounie et al.36 and are based
on 307 controls of Welsh origin. Frequencies for DM1 were obtained from Fig. 1 of
Ambrose et al.35 and are based on 254 controls of Chinese origin. Frequencies for
HDL were obtained from Fig. 1 of Figley et al.34 and are based on 352 controls of
North American Caucasian origin. Frequencies for SCA7 were obtained from Fig. 1
of Gouw et al.33 and are based on 180 controls of European origin. Frequencies for
HTT are based on data in the phv00173896.v1.p1 variable of dbGaP study
phs000371.v1.p1 (Genetic modifiers of Huntington’s Disease) based on the shorter
allele of 2802 patients with Huntington’s Disease.
Phasing SNPs in the SSC. SNP genotypes were phased using SHAPEIT69 version
2.r837 with 1000 Genomes Phase 3 genotypes as a reference panel and ignoring
pedigree information. SHAPEIT’s duoHMM70 version 0.1.7 method was used to
refine phased haplotypes using pedigree structure and correcting for Mendelian
errors.
Phasing STRs. Beagle40 version 4.0 was used to phase each STR separately using
phased SNP genotypes, pedigree information, and unphased STR genotypes as
input. In order to leverage the HipSTR genotype likelihoods (GL field), Beagle
requires all samples to have GL information. To accommodate this, phasing was
performed in two steps. First, samples with missing data were removed and the
remaining samples were phased using the -gl Beagle flag. Next, missing samples
were added back to the VCF and all samples were jointly phased in a second Beagle
round using default parameters. In this step Beagle additionally imputed any calls
with missing genotypes. Genotype values (GT field) were used for the STRs gen-
otyped using Tredparse as it does not report genotype likelihoods, and phasing and
imputation of STRs was done in a single step. Phased STRs and SNPs for only the
unrelated parent samples from each locus were then merged into a single genome-
wide reference panel in VCF format.
Imputation performance metrics. Let X= {x1, x2,...xn} be the true STR genotypes
for samples 1..n and Y= {y1, y2,...yn} be the imputed STR genotypes. Each gen-
otype xi is defined as xi= (xi1, xi2) where xi1 and xi2 give the (unordered) lengths of
the two STR alleles for a diploid sample and similarly for Y. We then define the
following metrics:
Genotype concordance ci was defined as: 1 if both genotypes match (xi1 =
yi1and xi2 = yi2 or xi2 = yi1and xi1 = yi2); 0 if neither imputed allele matched a true
allele; else 0.5 if one but not both imputed alleles matched the true alleles. Genotype
concordance for an STR is the average over all the samples C ¼ 1n
Pn
i¼1 ci .
Define the STR genotype dosage as the sum of the lengths of the two alleles at a
given site: di= xi1 + xi2 and Xd= {d1, d2,...,dn}. Length r2 is computed as
cov2ðXd ;YdÞ= VarðXdÞVarðYdÞð Þ:
For a given allele length a, define Xa= {a1, a2,...,an} where ai ¼
P2
j¼1 1ðxij¼aÞ.
Allelic r2 is computed as cov2(Xa, Ya)/(Var(Xa)Var(Ya)).
The best tag SNP for an STR is defined as the SNP within 50 kb with the highest
length r2.
For all concordance metrics, outlier genotypes containing alleles seen less than
three times in the entire cohort were removed from the analysis.
For each STR, we additionally computed the expected value of each metric
under a random model where genotypes are imputed randomly based on the
frequency of underlying alleles and a naive model where genotypes are imputed to
be the most common diploid genotype. Expected genotype concordance under the
random model was calculated as
P
i;j fifj
P
k;l Cði; j; k; lÞ
 
, where (i, j) ∈ {1,...,n}2
and (k, l) ∈ {1,...,n}2, n is the number of alleles, fx gives the frequency of allele x, and
C(i, j, k, l) gives the concordance between genotypes (i, j) and (k, l) as defined
above. For example, for a bi-allelic marker with allele frequencies f1 and f2
expected genotype concordance under the random model is given by
f 21 f
2
1 þ ð0:5Þ2ðf1Þðf2Þ
 þ 2f1f2ðð0:5Þf 21 þ 2f1f2 þ ð0:5Þf 22 Þ þ f 22 f 22 þ ð0:5Þ2f1f2
 
.
Random model values for length r2 and allelic r2 were computed by comparing
genotypes imputed randomly based on population allele frequencies to true
genotypes at each STR. Concordance under the naive model was computed by
comparing each sample’s genotype to the most frequent diploid genotype. Length
r2 and allelic r2 are not defined under the naive model since all imputed genotypes
are identical.
Evaluating imputation performance in the 1000 Genomes data. STRs were
imputed into SNP data downloaded from the 1000 Genomes Project site from three
sources (WGS, phased SNPs from Affy6.0 array; and phased SNPs from Omni2.5
array; see URLs and Supplementary Table 3) with Beagle version 4.1 using the SSC
SNP-STR haplotype panel. For comparison to WGS, STRs were jointly genotyped
in high-coverage WGS datasets for 150 of the 1000 Genomes Project samples (see
URLs) using HipSTR version 0.6 followed by the filtering steps described above for
the SSC cohort.
Capillary electrophoresis genotypes for 209 samples at 721 Marshfield STRs
were downloaded from the Payseur Lab website (see URLs). PCR product sizes
were converted to length differences in bp from the reference genome using
product size annotations71 available from the Rosenberg Lab website (see URLs).
Prior to comparing genotypes, offsets were calculated to match HipSTR lengths to
the length of Marshfield STRs as previously described14. STRs with imperfect
repeat structures were removed. Capillary genotypes were rounded down to the
nearest number of repeat units.
10X Genomics data for NA12878 was obtained from the NA12878 Gemline
Genome v2 available on the 10X Genomics website (see URLs). We extracted reads
belonging to phase 1 or 2 from the phased, barcoded BAM based on the HP tag
into separate BAM files. HipSTR v0.6.1 was called separately on each BAM with
non-default parameters --def-stutter-model --min-reads 5 --use-unpaired and
with --haploid-chrs containing a list of all autosomal chromosomes to force a
haploid genotyping model. Haploid STR calls were obtained for both phases at
118,353 STRs. We identified the nearest heterozygous SNP to each STR that was
genotyped in both the 10X data and in our phased panel. STRs for which the
nearest SNP had discordant genotypes in the two datasets were discarded leaving
116,764 STRs for analysis.
Simulations for power analysis. We analyzed parental genotypes for 5838 STRs
across chromosome 21 that passed filtering and quality control as described above.
For each STR, we simulated quantitative phenotype datasets under the model: P=
βG+ E, where P is a vector of standard normalized phenotypes, β gives the effect
size, E gives the error term drawn from a normal distribution N(0,1−β), and G is a
vector of the sum of genotype lengths for each individual scaled to have mean 0
and variance 1. For each simulated phenotype dataset, we tested the causal STR, the
imputed STR genotypes, and the best tag SNP (strongest length r2) within 50 kb of
the STR for association. Association tests were performed using the Python
statsmodels library OLS method (see URLs).
We performed additional simulations under a case–control model shown in
Supplementary Fig. 8. Phenotypes (0= control, 1= case) were drawn for each
sample according to the model logit (pi) = βXi where pi is the probability that
sample i is a case and Xi is the scaled genotype for individual i as described above.
Association tests were performed using the Python statsmodels Logit method.
For the non-additive phenotype example (Supplementary Fig. 9), we performed
simulations under a quadratic model: P= βG2+ E where G is a vector of the
squared sum of allele lengths scaled by the mean allele length, and P, β, E are as
described above. Two sets of association tests were performed: the first tested for
association between STR length and phenotype (Supplementary Fig. 9b) and the
second set performed a separate association test for each STR allele treating the
allele as a bi-allelic locus (Supplementary Fig. 9c).
In all cases 100 separate simulations were performed and power was defined as
the percent of simulations for which the nominal association p-value was <0.05.
Figures show results for all simulations with β set to 0.1.
eSTR analysis. Data for eSTR analysis was obtained from the Genotype-Tissue
Expression (GTEx) through dbGaP under phs000424.v7.p2. This included high-
coverage (30 × ) Illumina whole-genome sequencing (WGS) data from 650 unre-
lated samples, Omni 2.5 SNP genotypes for 450 samples, and gene-level RPKM
values for whole blood in 336 samples. STRs were genotyped from WGS data using
HipSTR v0.5 and subject to the same quality filtering as SSC samples. STRs were
additionally imputed to Omni2.5 data with Beagle as described above. Downstream
analyses were restricted to the 336 samples with available whole blood expression
data. These samples consisted of 284 European, 45 African American, 3 Asian, and
3 Amerindian samples and 2 samples with no population label available.
We performed separate eSTR analyses using HipSTR and imputed genotypes.
In each case, we performed a separate association test between gene expression and
each STR within 100 kb of the gene using a model Y= βX+ C+ ε, where X
denotes STR genotype lengths, Y denotes expression values, β denotes the effect
size, C denotes various covariates, and ε is the error term. Following our previous
study17, we used STR dosage, defined as the sum of repeat lengths of the two alleles
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for each sample, to define STR genotypes. All repeat lengths are reported as length
differences from the hg19 reference, with 0 representing the reference allele. STR
dosages were scaled to have mean 0 and variance 1. Genes with median expression
of 0 were excluded and expression values for remaining genes were quantile
normalized to a standard normal distribution. We included sex, population
structure, and technical variation in expression as covariates. For population
structure, we used the top 15 principal components resulting from perform
principal components analysis on the matrix of SNP genotypes from each sample.
To control for technical variation in expression, we applied PEER factor
correction72,73 using 83 PEER factors.
We used model comparison to determine whether the best eSTR for each gene
explained variation in gene expression beyond a model consisting of the best eSNP.
For each gene with an eSTR we determined the lead eSNP with the strongest p-
value. We then compared two linear models: Y ~ eSNP (SNP-only model) vs. Y ~
eSNP+ eSTR (SNP+ STR model) using the anova_lm function in the python
statsmodels.api.stats module. We used CAVIAR v1.0 to further fine-map eSTR
signals against the top 100 eSNPs within 100 kb of each gene. Pairwise-LD between
the eSTR and eSNPs was estimated using the Pearson correlation between SNP
dosages (0, 1, or 2) and STR dosages (sum of the two repeat allele lengths).
Comparison to DRPLA founder haplotypes. The founder haplotype for the
expansion allele in ATN1 implicated in DRPLA was taken from Table 1 of
Veneziano et al.55 and consists of rs4963516, rs1007924, rs7310941, rs7303722,
rs2239167, rs34199021, rs2071075, rs2071076, and rs2159887 with hg19 alleles G,
A, G, T, A, A, T, C, and C, respectively. Distance from the founder haplotype was
calculated as the number of mismatches.
URLs. For Simons Simplex Collection, see https://base.sfari.org/. For HipSTR, see
https://github.com/tfwillems/HipSTR. For Beagle, see https://faculty.washington.
edu/browning/beagle/b4_0.html. For 1000 Genomes phased Affy6.0 and Omni2.5
SNP data, see ftps.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/
shapeit2_scaffolds/hd_chip_scaffolds/. For 1000 Genomes Phase 3, see http://
ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/. For 1000 Genomes STR
data, see http://strcat.teamerlich.org/download. For Marshfield Capillary electro-
phoresis data, see https://payseur.genetics.wisc.edu/strpData.htm. For Marshfield
marker annotations, see https://web.stanford.edu/group/rosenberglab/data/
pembertonEtAl2009/Pemberton_AdditionalFile1_11242009.txt. For NA12878 10X
Genomics data, see https://support.10xgenomics.com/genome-exome/datasets/
2.2.1/NA12878_WGS_v2. For High-coverage Illumina sequencing for 1000 Gen-
omes samples, see https://www.ebi.ac.uk/ena/data/view/PRJEB20654. For PyVCF,
see https://github.com/jamescasbon/PyVCF. For Python statsmodels, see http://
www.statsmodels.org/stable/index.html.
Code availability. Analysis scripts and Jupyter notebooks for reproducing the
figures in this study are provided in the Github repository https://github.com/
gymreklab/snpstr-imputation.
Data availability
Phased SNP-STR haplotypes for 1000 Genomes Project phase 3 samples and example
commands for imputation are available from Gymrek Laboratory webpage [https://
gymreklab.github.io/2018/03/05/snpstr_imputation.html]. Phased SNP-STR haplotypes
for the SSC samples are available through SFARI base Accession Code:
SFARI_SSC_WGS_1c. 1000 Genomes phased Affy6.0 and Omni2.5 SNP data are
available through the 1000 Genomes FTP server [ftp.1000genomes.ebi.ac.uk/vol1/ftp/
release/20130502/supporting/shapeit2_scaffolds/hd_chip_scaffolds/]. 1000 Genomes
phase 3 Whole-Genome Sequencing data is available through the 1000 Genomes FTP
server [http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/]. 1000 Genomes STR
data is available from strcat [http://strcat.teamerlich.org/download]. Marshfield Capillary
electrophoresis data is available from the Payseur Laboratory webpage [https://payseur.
genetics.wisc.edu/strpData.htm]. Marshfield marker annotations are available from the
Rosenberg Laboratory webpage [https://web.stanford.edu/group/rosenberglab/data/
pembertonEtAl2009/Pemberton_AdditionalFile1_11242009.txt]. NA12878 10X Geno-
mics data is available at the 10X Genomics Datasets Repository [https://
support.10xgenomics.com/genome-exome/datasets/2.2.1/NA12878_WGS_v2]. High-
coverage Illumina sequencing for 1000 Genomes samples is available from the European
Nucleotide Archive Accession Code PRJEB20654
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